- Home
- LFT vs BDSX Comparison
LFT vs BDSX Comparison
Compare LFT & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | BDSX |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.4M | 88.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LFT | BDSX |
|---|---|---|
| Price | $1.34 | $9.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 234.8K | ★ 4.2M |
| Earning Date | 03-18-2026 | 03-02-2026 |
| Dividend Yield | ★ 11.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | $21,708,246.00 | ★ $80,173,000.00 |
| Revenue This Year | $124.75 | $22.01 |
| Revenue Next Year | N/A | $26.81 |
| P/E Ratio | $14.23 | ★ N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $1.30 | $3.44 |
| 52 Week High | $2.84 | $21.60 |
Technical Indicators
Market Signals| Indicator | LFT | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 54.04 |
| Support Level | $1.44 | $10.02 |
| Resistance Level | $1.46 | $11.49 |
| Average True Range (ATR) | 0.05 | 1.72 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 2.18 | 56.59 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.